Gender-affirming hormone therapy (GAHT) for transgender women (TGW) transition is typically based on a combination of estrogens and androgen deprivation therapy [1]. This treatment is designed to recalibrate the hormonal balance in TGW. GAHT promotes the development of female secondary sexual characteristics; in addition, it has a significant impact on mood, cognitive status, and behavior [2]. The biological and potentially pathological adaptations that male genitalia—particularly the prostate—undergo during the TGW transition remain unclear and source of several questions.
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications / Bologna, Eugenio; Licari, Leslie Claire; Franco, Antonio; Ditonno, Francesco; Leonardo, Costantino; De Nunzio, Cosimo; Autorino, Riccardo; Manfredi, Celeste. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - (2024). [10.1038/s41391-024-00796-1]
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications
Bologna, Eugenio;Licari, Leslie Claire;Franco, Antonio;Ditonno, Francesco;Leonardo, Costantino;De Nunzio, Cosimo;
2024
Abstract
Gender-affirming hormone therapy (GAHT) for transgender women (TGW) transition is typically based on a combination of estrogens and androgen deprivation therapy [1]. This treatment is designed to recalibrate the hormonal balance in TGW. GAHT promotes the development of female secondary sexual characteristics; in addition, it has a significant impact on mood, cognitive status, and behavior [2]. The biological and potentially pathological adaptations that male genitalia—particularly the prostate—undergo during the TGW transition remain unclear and source of several questions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
